[go: up one dir, main page]

WO2006096810A3 - Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0] hexanes - Google Patents

Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0] hexanes Download PDF

Info

Publication number
WO2006096810A3
WO2006096810A3 PCT/US2006/008436 US2006008436W WO2006096810A3 WO 2006096810 A3 WO2006096810 A3 WO 2006096810A3 US 2006008436 W US2006008436 W US 2006008436W WO 2006096810 A3 WO2006096810 A3 WO 2006096810A3
Authority
WO
WIPO (PCT)
Prior art keywords
aryl
azabicyclo
hexanes
methods
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/008436
Other languages
French (fr)
Other versions
WO2006096810A2 (en
Inventor
Phil Skolnick
Anthony Basile
Zhengming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DOV Pharmaceutical Inc
Original Assignee
DOV Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DOV Pharmaceutical Inc filed Critical DOV Pharmaceutical Inc
Priority to EP06737597A priority Critical patent/EP1874298A4/en
Priority to CA002640120A priority patent/CA2640120A1/en
Publication of WO2006096810A2 publication Critical patent/WO2006096810A2/en
Publication of WO2006096810A3 publication Critical patent/WO2006096810A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention provides novel l-aryl-3-azabicyclo[3.1.0] hexanes that are active for modulating biogenic amine transport, along with compositions and methods for using these compounds to treat central nervous system disorders. Certain l-aryl-3-azabicyclo[3.1.0] hexanes are provided that have at least one substituent on the aryl ring. In other embodiments l-aryl-3-azabicyclo[3.1.0] hexanes are provided that have a substitution on the nitrogen at the '3' position. In additional embodiments l-aryl-3-azabicyclo[3.1.0] hexanes are provided which have one substitution on the aryl ring, as well as a substitution on the nitrogen at the '3' position. The invention also provides novel methods of making aryl- and aza-substituted l-aryl-3-azabicyclo[3.1.0] hexanes, including synthetic methods that form novel intermediate compounds of the invention for producing aryl- and aza-substituted l-aryl-3-azabicyclo[3.1.0] hexanes.
PCT/US2006/008436 2005-03-08 2006-03-07 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0] hexanes Ceased WO2006096810A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06737597A EP1874298A4 (en) 2005-03-08 2006-03-07 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3,1,0]hexanes
CA002640120A CA2640120A1 (en) 2005-03-08 2006-03-07 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo(3.1.0) hexanes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66166205P 2005-03-08 2005-03-08
US60/661,662 2005-03-08
US70156205P 2005-07-22 2005-07-22
US60/701,562 2005-07-22

Publications (2)

Publication Number Publication Date
WO2006096810A2 WO2006096810A2 (en) 2006-09-14
WO2006096810A3 true WO2006096810A3 (en) 2006-10-19

Family

ID=36954024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/008436 Ceased WO2006096810A2 (en) 2005-03-08 2006-03-07 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0] hexanes

Country Status (4)

Country Link
US (1) US20060223875A1 (en)
EP (1) EP1874298A4 (en)
CA (1) CA2640120A1 (en)
WO (1) WO2006096810A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
CA2659215C (en) 2005-07-27 2018-07-10 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
EP2016053B1 (en) * 2006-04-28 2010-11-10 Merck Sharp & Dohme Corp. Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
GB0625198D0 (en) 2006-12-18 2007-01-24 Glaxo Group Ltd Chemical compounds
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0809479D0 (en) * 2008-05-23 2008-07-02 Glaxo Group Ltd Novel compounds
CA2746055C (en) * 2008-12-16 2016-12-13 Sunovion Pharmaceuticals Inc. Triple reuptake inhibitors and methods of their use
EP2393357B1 (en) * 2009-02-09 2015-08-26 Sunovion Pharmaceuticals Inc. Pyrrolidine triple reuptake inhibitors
CA2765692A1 (en) 2009-06-26 2010-12-29 Panacea Biotec Ltd. Novel azabicyclohexanes
BR112013007566A2 (en) 2010-09-28 2016-08-02 Panacea Biotec Ltd new bicyclic compounds
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
US9839627B2 (en) 2013-12-09 2017-12-12 Neurovance, Inc. Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
WO2020142545A1 (en) 2018-12-31 2020-07-09 Ethismos Research, Inc. Novel methods
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142904A1 (en) * 2002-10-25 2004-07-22 Rariy Roman V. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
IE46233B1 (en) * 1977-09-15 1983-04-06 American Cyanamid Co Azabicyclohexanes, methods of preparation thereof, and pharmaceutical compositions containing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142904A1 (en) * 2002-10-25 2004-07-22 Rariy Roman V. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHUTO S.: "Synthesis of (+)- and (-)-Milnaciprans and Their Conformationally Restricted Analogs", TETRAHEDRON LETTERS, vol. 37, no. 5, 1996, pages 641 - 644, XP004030321 *

Also Published As

Publication number Publication date
US20060223875A1 (en) 2006-10-05
CA2640120A1 (en) 2006-09-14
EP1874298A2 (en) 2008-01-09
EP1874298A4 (en) 2009-08-05
WO2006096810A2 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
WO2006096810A3 (en) Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0] hexanes
WO2005123703A8 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
WO2008062276A8 (en) Acetylene derivatives as stearoyl coa desaturase inhibitors
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
WO2008081399A3 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
WO2007018998A3 (en) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
WO2004108133A3 (en) Modulators of vr1 receptor
WO2009118596A3 (en) Phthalimide derivatives as trpa1 modulators
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
WO2006136357A3 (en) Crystalline modifications to pyraclostrobin
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
GB0510143D0 (en) Novel compounds A1
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
MY149422A (en) 5-(arylsulfonyl)-pyrazolopiperidines
WO2008010061A3 (en) 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors
WO2007109288A3 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008500921

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006737597

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

NENP Non-entry into the national phase

Ref country code: JP

WWE Wipo information: entry into national phase

Ref document number: 2640120

Country of ref document: CA